Dr. Lin Yang 杨林
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment for digestive system tumors, including gastric, colorectal, pancreatic, liver, biliary tract cancers and gastrointestinal stromal tumors.
Dr. Yang holds a medical doctorate and is a chief physician. With over 20 years of experience in medical oncology and clinical research on new anti-cancer drugs, Dr. Yang specializes in the medical treatment of digestive system tumors.
Name order: in Chinese the family name comes first (Yang Lin). Papers usually list the name as Lin Yang or Yang L.
Selected publications
205 papers on PubMed matched by name and affiliation; 57 as first or senior author since 2016. Most recent first- or senior-author papers:
- Crit Rev Oncol Hematol, 2026 (senior author): Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. PubMed 42998776
- NPJ Digit Med, 2026 (first author): Deep learning based histomorphological phenotyping and prognostic stratification for combined SCLC and LCNEC. PubMed 42218257
- Int J Cancer, 2026 (senior author): Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study. PubMed 41449829
- Discov Oncol, 2026 (senior author): First-line PD-1 inhibitor plus chemotherapy improves outcomes in advanced gastric cancer and correlates with specific biomarkers in a real-world cohort. PubMed 41863740
- Pharmacol Res, 2025 (senior author): Spatial proteomic profiling reveals conserved prognostic immune microenvironment features across molecular subtypes in small cell lung cancer. PubMed 41290052
- Front Immunol, 2025 (senior author): Inhibition of human gastric cancer growth by cytokine-induced killer cells plus chemotherapy with or without cadonilimab in a mouse xenograft tumor model. PubMed 40539041
- Brief Bioinform, 2025 (senior author): DeepTFtyper: an interpretable morphology-aware graph neural network for translating histopathology images into molecular subtypes in small cell lung cancer. PubMed 40539233
- Research (Wash D C), 2025 (senior author): Proteogenomic Characterization of High-Grade Lung Neuroendocrine Carcinoma Deciphers Molecular Diversity and Potential Biomarkers of Different Histological Subtypes in Chinese Population. PubMed 40230612
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion